Control of atrial natriuretic peptide secretion in patients with severe congestive heart failure.
Congestive heart failure (CHF) is marked by activation of multiple hormone systems that increased peripheral vasoconstriction and produce sodium and water retention. Plasma atrial natriuretic peptide (ANP) levels are frequently elevated in patients with severe CHF and may act to counterbalance these hormonal actions. To determine whether CHF patients maintain a physiological response to the presumed major stimulus to ANP secretion, atrial stretch, 22 CHF patients and 8 normal volunteers were studied. Atrial distention was produced in 10 CHF patients with a mannitol infusion and in 12 with lower body positive pressure. Eight normal volunteers also underwent a mannitol infusion. Both stimuli provoked increases in plasma ANP levels in the CHF patients, and the relative increase in plasma ANP after mannitol was similar in the CHF patients and the normal volunteers. We conclude that ANP secretion responds to atrial stretch in CHF patients, suggesting maintenance of the physiological release of this peptide.
Uretsky
B F
BF
Department of Medicine, Presbyterian-University Hospital, Pittsburgh, Pennsylvania 15213.
Verbalis
J G
JG
Murali
S
S
Betschart
A R
AR
Kolesar
J A
JA
Reddy
P S
PS
D000328:Adult; D001127:Arginine Vasopressin / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood* / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects; D001810:Blood Volume / Q000187:drug effects; D001834:Body Water / Q000378:metabolism; D005260:Female; D006333:Heart Failure / Q000097:blood*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000494:pharmacology; D008875:Middle Aged; D012964:Sodium / Q000378:metabolism; D014661:Vasoconstriction / Q000187:drug effects
D001127:Arginine Vasopressin; D008353:Mannitol; D009320:Atrial Natriuretic Factor; D012964:Sodium